L & S Advisors Inc Acquires 1,400 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)

L & S Advisors Inc increased its position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC) by 2.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 59,735 shares of the company’s stock after acquiring an additional 1,400 shares during the quarter. L & S Advisors Inc owned about 0.13% of Bicycle Therapeutics worth $1,352,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Baker BROS. Advisors LP increased its holdings in Bicycle Therapeutics by 176.1% during the first quarter. Baker BROS. Advisors LP now owns 4,942,823 shares of the company’s stock worth $123,076,000 after buying an additional 3,152,433 shares during the last quarter. Armistice Capital LLC lifted its position in Bicycle Therapeutics by 17.9% during the second quarter. Armistice Capital LLC now owns 1,972,000 shares of the company’s stock worth $39,913,000 after purchasing an additional 300,000 shares during the period. First Light Asset Management LLC lifted its position in Bicycle Therapeutics by 16.1% during the second quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company’s stock worth $28,028,000 after purchasing an additional 191,717 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in Bicycle Therapeutics by 0.6% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company’s stock worth $17,975,000 after acquiring an additional 4,976 shares in the last quarter. Finally, Avoro Capital Advisors LLC acquired a new position in Bicycle Therapeutics during the second quarter worth about $14,168,000. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Stock Performance

Shares of Bicycle Therapeutics stock opened at $20.35 on Friday. The stock has a 50 day moving average price of $24.23 and a 200-day moving average price of $23.08. Bicycle Therapeutics plc has a one year low of $13.31 and a one year high of $28.67. The stock has a market cap of $967.40 million, a price-to-earnings ratio of -6.11 and a beta of 0.89.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. The business had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. Bicycle Therapeutics’s revenue was down 50.0% on a year-over-year basis. During the same period in the previous year, the company posted ($1.26) EPS. Sell-side analysts predict that Bicycle Therapeutics plc will post -3.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Stephens assumed coverage on Bicycle Therapeutics in a research note on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of Bicycle Therapeutics in a report on Friday, November 1st. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Bicycle Therapeutics in a report on Monday, September 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.13.

Insider Buying and Selling at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 3,212 shares of the stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total value of $71,499.12. Following the completion of the transaction, the chief executive officer now directly owns 380,864 shares in the company, valued at approximately $8,478,032.64. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Travis Alvin Thompson sold 6,256 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $25.11, for a total value of $157,088.16. Following the transaction, the chief accounting officer now directly owns 19,241 shares in the company, valued at approximately $483,141.51. This represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,840 shares of company stock worth $259,128. 8.50% of the stock is currently owned by insiders.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.